Skye Bioscience, Inc. Quarterly Debt-to-equity in % from Q4 2013 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Skye Bioscience, Inc. quarterly Debt-to-equity history and growth rate from Q4 2013 to Q2 2024.
  • Skye Bioscience, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 38.6 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 38.6 +238 Jun 30, 2024
Q1 2024 76.4 +366 Mar 31, 2024
Q4 2023 -364 +403 +52.5% Dec 31, 2023
Q3 2023 -327 -701 -187% Sep 30, 2023
Q2 2023 -200 -300 -298% Jun 30, 2023
Q1 2023 -289 -366 -477% Mar 31, 2023
Q4 2022 -767 -839 -1169% Dec 31, 2022
Q3 2022 374 +287 +328% Sep 30, 2022
Q2 2022 101 -53.2 -34.5% Jun 30, 2022
Q1 2022 76.7 -572 -88.2% Mar 31, 2022
Q4 2021 71.8 +490 Dec 31, 2021
Q3 2021 87.5 +490 Sep 30, 2021
Q2 2021 154 +276 Jun 30, 2021
Q1 2021 649 +775 Mar 31, 2021
Q4 2020 -418 -297 -246% Dec 31, 2020
Q3 2020 -402 -286 -247% Sep 30, 2020
Q2 2020 -122 -5.63 -4.82% Jun 30, 2020
Q1 2020 -126 -9.6 -8.28% Mar 31, 2020
Q4 2019 -121 +0.14 +0.12% Dec 31, 2019
Q3 2019 -116 -1.09 -0.95% Sep 30, 2019
Q2 2019 -117 -6.14 -5.55% Jun 30, 2019
Q1 2019 -116 -19.2 -19.9% Mar 31, 2019
Q4 2018 -121 -58.2 -92.7% Dec 31, 2018
Q3 2018 -115 -45.3 -64.9% Sep 30, 2018
Q2 2018 -111 -42.2 -61.7% Jun 30, 2018
Q1 2018 -96.8 -28.6 -42% Mar 31, 2018
Q4 2017 -62.8 +25.4 +28.8% Dec 31, 2017
Q3 2017 -69.7 +60.5 +46.5% Sep 30, 2017
Q2 2017 -68.4 +137 +66.7% Jun 30, 2017
Q1 2017 -68.1 +178 +72.3% Mar 31, 2017
Q4 2016 -88.2 +249 +73.8% Dec 31, 2016
Q3 2016 -130 +173 +57% Sep 30, 2016
Q2 2016 -206 Jun 30, 2016
Q1 2016 -246 Mar 31, 2016
Q4 2015 -337 Dec 31, 2015
Q3 2015 -303 Sep 30, 2015
Q2 2014 682 Jul 31, 2014
Q1 2014 910 Apr 30, 2014
Q4 2013 1.2K Dec 31, 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.